CYCN · As filed with the SEC
Korsana Biosciences balance sheet, by fiscal year
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | 3,240,000 | 3,232,000 | 7,571,000 | 13,382,000 |
| Accounts receivable | 1,000,000 | 556,000 | 0 | 96,000 |
| Prepaid expenses | 384,000 | 421,000 | 442,000 | 805,000 |
| Other current assets | 11,000 | 16,000 | 11,000 | 537,000 |
| Total current assets | 4,635,000 | 4,225,000 | 8,024,000 | 14,820,000 |
| Property and equipment, net | — | — | — | 0 |
| Operating lease right-of-use asset | — | — | 0 | 1,218,000 |
| Other investment | 5,350,000 | 5,350,000 | 5,350,000 | — |
| Other assets | — | — | 0 | 2,041,000 |
| Total assets | 9,985,000 | 9,575,000 | 13,374,000 | 18,079,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current liabilities: | ||||
| Accounts payable | 508,000 | 390,000 | 1,198,000 | 2,970,000 |
| Accrued research and development costs | 198,000 | 52,000 | 90,000 | 2,275,000 |
| Accrued expenses and other current liabilities | 194,000 | 283,000 | 798,000 | 2,382,000 |
| Total current liabilities | 900,000 | 725,000 | 2,086,000 | 7,627,000 |
| Commitments and contingencies (Note 6) | 0 | 0 | 0 | 0 |
| Stockholders' equity | ||||
| Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | — |
| Common stock, no par value, 400,000,000 shares authorized at December 31, 2025 and 2024; 3,925,314 and 2,710,096 shares issued at December 31, 2025 and 2024, respectively; 3,821,236 and 2,545,922 shares outstanding at December 31, 2025 and 2024, respectively | 0 | 0 | 0 | 0 |
| Paid-in capital | 280,105,000 | 276,342,000 | 275,717,000 | 269,626,000 |
| Accumulated deficit | (271,020,000) | (267,492,000) | (264,417,000) | (259,154,000) |
| Accumulated other comprehensive loss | — | 0 | (12,000) | (20,000) |
| Total stockholders' equity | 9,085,000 | 8,850,000 | 11,288,000 | 10,452,000 |
| Total liabilities and stockholders' equity | 9,985,000 | 9,575,000 | 13,374,000 | 18,079,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.